The agenda aims to bring together pharma, biotech, CROs with regulatory bodies and legal experts explaining the advantages and disadvantages within this growing market, looking at case studies from those who are developing and distributing follow on biologics with analysis of key trends in biologic pipelines, methods in clinical trials for biosimilar approval, a review of emerging markets, assessment of biosimilar manufacturing, post approval strategy and future forecasting for follow on biologics. KEY REASONS TO ATTENDDiscover guidelines issues by regulatory bodies such as the FDA & EMEA and how they impact your business modelUnderstand market access pathways and see case studies on successful productsHear development processes from preclinical focussed research from big pharma companiesLearn from expert legal opinions on intellectual property and patent protection programmesEvaluate global research co-operation producing blockbuster BiosimilarsDevelop clinical plan for biosimilar and biobetter drug design for your clinical trial - When is the right time to proceedKEYNOTE SPEAKERS INCLUDE:Richard Dicicco, Chairman, Harvest Moon PharmaceuticalsEdward Ghabour, Head of Strategic Planning, NovartisJosh Adelson, Director, Commercial Development, Business Development Biosimilars, PfizerHaiyan Jing, Senior Director, Biogen IdecMalcolm Mitchell, Senior Medical Fellow, Eli Lilly & CoThomas Klein, IP Specialist, RocheJennifer Campbell, Director Worldwide Biosimilars Programme, Merck Millipore Steinar Madsen, Medical Director, Norwegian Medicines Agency